Advertisement
Advertisement
BMY
Bristol-Myers Squibb Co.
63.83
USDSponsored
-0.82
-1.27%
Aug 14, 15:59 UTC -4
Closed
After-Market
63.99
+0.16
+0.26%
BMY Earnings Reports
Positive Surprise Ratio
BMY beat 37 of 42 last estimates.
88%
Next Report
Date of Next Report
Oct 29, 2026
Estimate for Q3 26 (Revenue/ EPS)
$12.68B
/$1.73
Implied change from Q2 26 (Revenue/ EPS)
-2.24%
/-15.20%
Implied change from Q3 25 (Revenue/ EPS)
+3.77%
/+6.13%
Bristol-Myers Squibb Co. earnings per share and revenue
On Jul 30, 2026, BMY reported earnings of 2.04 USD per share (EPS) for Q2 26, beating the estimate of 1.60 USD, resulting in a 27.20% surprise. Revenue reached 12.97 billion, compared to an expected 11.86 billion, with a 9.36% difference. The market reacted with a +2.79% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 10 analysts forecast an EPS of 1.73 USD, with revenue projected to reach 12.68 billion USD, implying an decrease of -15.20% EPS, and decrease of -2.24% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
$0.11
Actual
$0.35
Surprise
+198.38%
Cabaletta Bio, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.34
Surprise
+10.69%
Caribou Biosciences, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.32
Actual
-$0.24
Surprise
+25.74%
TuHURA Biosciences, Inc. Common Stock
Report Date
Aug 14, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.14
Surprise
+5.34%
ADC Therapeutics SA
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.21
Actual
-$0.11
Surprise
+49.12%
Outlook Therapeutics, Inc. Common Stock
Report Date
Aug 14, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.09
Surprise
+5.46%
Pelthos Therapeutics Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$3.10
Actual
-$6.62
Surprise
-112.99%
Elutia Inc. Class A Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.15
Actual
-$0.17
Surprise
-11.11%
Lantern Pharma Inc. Common Stock
Report Date
Aug 14, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.28
Surprise
+27.76%
Kyntra Bio, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$3.24
Actual
-$4.68
Surprise
-44.15%
FAQ
What were Bristol-Myers Squibb Co.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Bristol-Myers Squibb Co. reported EPS of $2.04, beating estimates by 27.2%, and revenue of $12.97B, 9.36% above expectations.
How did the market react to Bristol-Myers Squibb Co.'s Q2 2026 earnings?
The stock price moved up 2.79%, changed from $63.10 before the earnings release to $64.86 the day after.
When is Bristol-Myers Squibb Co. expected to report next?
The next earning report is scheduled for Oct 29, 2026.
What are the forecasts for Bristol-Myers Squibb Co.'s next earnings report?
Based on 10
analysts, Bristol-Myers Squibb Co. is expected to report EPS of $1.73 and revenue of $12.68B for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement